Company Profile
Frst Capital is a venture capital firm that specializes in early-stage investments, often referred to as "Day One" funding. The firm is dedicated to identifying and supporting a new generation of ambitious European entrepreneurs with global aspirations. They are known for making significant initial investments, sometimes even before a company has a team, product, or is formally incorporated, with an average first check of $2 million. Frst Capital aims to be a responsive, reliable, and knowledgeable partner, fostering long-term relationships with its portfolio companies.
The firm was co-founded by Pierre Entremont and Bruno Raillard. Their partnership in seed investing began in 2015, and they officially launched Frst Capital as an independent entity in 2019, spinning off from Otium Capital. Pierre Entremont brings a diverse background spanning entrepreneurship, company building, private equity, and management consulting. Bruno Raillard's experience includes financial consulting, private equity investment, and general management across various company sizes.
Frst Capital has a robust portfolio, having deployed $200 million into 70 companies since its inception, which have collectively raised $3.5 billion to date. Notable investments include companies like Pigment, Electra, PayFit, and Shippeo. The firm's portfolio also features unicorns such as Poolside, Pigment, and PayFit. Their investments span a wide array of sectors, including technology, financial services, biotech/life science, healthcare, business services, and consumer.
The team at Frst Capital comprises experienced professionals, including Co-Founders & Partners Pierre Entremont and Bruno Raillard, along with other partners and associates such as Gabriel de Vinzelles, Jerome Bestel, Louise Boucher, Jérémy Bestel, and Samuel Fitoussi. The firm's expertise is rooted in a deep understanding of company creation, growth, and market dynamics, enabling them to provide strategic guidance and support to their portfolio companies beyond just capital injection.
News & Signals (0)
No linked news activity found for this company.